Comparing Nutra Pharma (OTCMKTS:NPHC) and Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI) and Nutra Pharma (OTCMKTS:NPHC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Valuation and Earnings

This table compares Dyadic International and Nutra Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.42 million	10.31	-$5.81 million	($0.24)	-4.06
Nutra Pharma	$440,000.00	0.00	$8.18 million	N/A	N/A

Nutra Pharma has lower revenue, but higher earnings than Dyadic International.

Profitability

This table compares Dyadic International and Nutra Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyadic International	-134.84%	-355.39%	-60.66%
Nutra Pharma	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for Dyadic International and Nutra Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1	0	2	0	2.33
Nutra Pharma	0	0	0	0	0.00

Dyadic International currently has a consensus price target of $3.00, suggesting a potential upside of 207.69%. Given Dyadic International’s stronger consensus rating and higher possible upside, research analysts clearly believe Dyadic International is more favorable than Nutra Pharma.

Risk and Volatility

Dyadic International has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Nutra Pharma has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500.

Insider and Institutional Ownership

28.0% of Dyadic International shares are held by institutional investors. 29.5% of Dyadic International shares are held by insiders. Comparatively, 61.5% of Nutra Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Dyadic International beats Nutra Pharma on 6 of the 11 factors compared between the two stocks.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.